Uric Acid: Is Lower Better? There is good evidence that a serum urate less than 6 mg/dL is required to meaningfully reduce urate crystal and gout flare burden, but is even lower better and are there any tradeoffs? https://t.co/W5FsDC5FG0 https://t.co/7mRgkg00uV

Updated Algorithm for the Management of Restless Legs Syndrome Diagnose: chronic vs intermittent RLS (no need for polysomnography) Test Iron levels (& Rx if) Consider: remove exacerbators; walking/massage/heat; carbidopa/ levodopa; pramipexole or ropinirole; low potency opioids; https://t.co/XdzIipw1X8

Learn more about the fundamentals of CAR T-cell therapy and its investigational use in autoimmune disease. Sponsored by Bristol Myers Squibb. https://t.co/VvTOYY3tvz #CARTCellTherapy https://t.co/kaTom2dEnZ

True or False: EULAR recommends glucocorticoids alone, without additional agents, for remission induction in life-threatening ANCA-associated vasculitis. Did you get it right? Take this week's RheumIQ quiz at https://t.co/TBlB4pmnKa. https://t.co/4IsId6lJ4Y

In a claims analysis, 28.1% of patients with PsA had ≥1 predictor of IBD development at PsA diagnosis. 📊Which predictors had the highest association with future IBD? Click to learn more: https://t.co/x2pM0T9LWg Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/uDxtvPAgOK

True or False: There is an available antidote for colchicine overdose. Check your answer in this week's RheumIQ at https://t.co/TBlB4pmnKa. https://t.co/RgJ4xEAuZA

The mortality gap in gout has not improved in 20 years – CV disease is the leading cause of death (2-fold increase). For more gout content, follow our Gout: More than Flares campaign at https://t.co/xnBVBN5IXZ, https://t.co/c12GmMaatt

TNR: Gout Journal Club https://t.co/vWNEof3F6b https://t.co/EgfqfKU1lx

QD Clinic: Cellulitis Paradoxes Dr. Richard Conway, Dublin, discusses a case of cellulitis and gout. Presented as part of RheumNow's "Gout: More than Flares" campaign during the month of July 2026. https://t.co/ZeYyISJrrE https://t.co/2Ih4QRa7FK

FDA Delays Gout Drug NASP with Complete Response Letter On June 26, 2026, SOBI received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) that will delay a decision on NASP, pending the company's answer to questions regarding the drugs https://t.co/NmPbWmYd0p

Non-gout drugs that may lower uric acid – losartan, amlodipine, ACE inhibitors, fenofibrate, atorvastatin, leflunomide, vitamin C, estrogen, and high-dose ASA. For more gout content, follow our Gout: More than Flares campaign at https://t.co/xnBVBN5IXZ, https://t.co/vmNvqojAcS